Novartis Presents New Data On Early Symptom Relief And Long-Term Control In Complex Skin Diseases At AAD 2026

(MENAFN - GlobeNewsWire - Nasdaq) New Rhapsido– REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx– data ...